Compare AFCG & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFCG | SRTS |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.8M | 65.5M |
| IPO Year | 2020 | 2016 |
| Metric | AFCG | SRTS |
|---|---|---|
| Price | $2.56 | $4.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.50 | ★ $6.67 |
| AVG Volume (30 Days) | ★ 214.0K | 35.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $24,563,601.00 | ★ $27,482,000.00 |
| Revenue This Year | $1,334.03 | $2.00 |
| Revenue Next Year | $17.33 | $34.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.06 | $3.03 |
| 52 Week High | $5.87 | $5.92 |
| Indicator | AFCG | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 58.90 |
| Support Level | $2.49 | $3.66 |
| Resistance Level | $2.58 | $4.71 |
| Average True Range (ATR) | 0.14 | 0.28 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 5.95 | 88.61 |
Advanced Flower Capital Inc is an externally managed Maryland corporation that operates as a Business Development Company (BDC). The firm's primary operations involve originating, structuring, underwriting, and managing senior secured loans and other debt securities. Its investment portfolio includes loans to state law-compliant cannabis operators, ancillary cannabis businesses, and middle-market companies in other industries. These loans are typically secured by collateral such as real estate, equipment, cash flows, and license values.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.